Healio1d
Vutrisiran improves cardiac amyloidosis endpoints regardless of disease severity
Vutrisiran improved mortality and recurrent CV risks independent of disease severity and improved several other endpoints for ...
27 Analysts Assess Alnylam Pharmaceuticals: What You Need To Know
Analysts' ratings for Alnylam Pharmaceuticals ALNY over the last quarter vary from bullish to bearish, as provided by 27 ...
MPR3d
Amvuttra Gains Approval for Transthyretin Amyloid Cardiomyopathy
The Food and Drug Administration (FDA) has approved Amvuttra ® (vutrisiran) for the treatment of the cardiomyopathy of ...
Alnylam presents new data from HELIOS-B Phase 3 trial
Pharmaceuticals announced moderated poster presentations of new data from the HELIOS-B Phase 3 clinical trial, which evaluated ...
Le Lézard6d
FDA Approves Qfitliatm (fitusiran), the First siRNA (RNAi Therapeutic) for the Treatment of Hemophilia A or B
Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today highlighted the significance of the U.S. Food and Drug Administration's (FDA) approval of Qfitliatm (fitusiran), the sixth ...
Fierce Pharma6d
Sanofi's versatile Qfitlia scores FDA nod to enter crowded hemophilia market
Over the last three years, the FDA has approved six new hemophilia drugs, including three gene therapies. | Over the last ...
SA Asks: Which small/mid-cap cardiology stocks are undervalued?
Cardiology drug and device makers will be back in the spotlight this weekend as the annual scientific meeting of the American ...